Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApproaCH: TransCon CNP in Children with Achondroplasia
2022-002954-25Phase 2Active
- Sponsor
- Ascendis Pharma
- Start
- Nov 2022
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in achondroplasia (ACH) comparing TransCon CNP with Placebo (2 arms). Primary endpoint: AGV at Week 52. Started Nov 2022; status: active.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2022-002954-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002954-25.